As of February 2, 2026, the landscape for medical device manufacturing has officially shifted. The FDA has fully implemented the Quality Management System Regulation (QMSR), marking the most significant regulatory pivot in over 20 years.
With this shift comes a brand-new manual for investigators: Compliance Program 7382.850. If you are a Quality or Regulatory professional, this document should be on your reading list.
Is your team fully transitioned to QMSR, or are you still bridging the gap? Contact us to discuss your next steps.
What is New
The “QSIT” era is over. The FDA has harmonized its requirements with ISO 13485:2016, moving toward a global standard for quality management.
- Risk Management: Under CP 7382.850, investigators are no longer just looking at your CAPA logs; they are looking at how risk management is integrated into your entire product lifecycle.
- Total Product Life Cycle (TPLC): The manual consolidates general inspections and PMA pre-approval/post-market inspections into one unified strategy.
- Greater Transparency: Be prepared for deeper dives into management reviews and internal audits—areas that were previously more shielded during routine inspections.
The FDA is now auditing against a framework that mirrors international standards. For global manufacturers, this harmonization should eventually reduce the “audit fatigue” of managing different systems for different regions. However, the immediate challenge is ensuring that your legacy procedures align with the specific language and risk-based requirements of the QMSR.
The Takeaway
Don’t wait for an investigator to knock on your door to find out if your transition was successful. Review the updated CP 7382.850 today to see exactly what your investigator will be looking for.
